Related Experiment Video
Updated: Jun 3, 2026
04:01
Modeling Brain Tumors In Vivo Using Electroporation-Based Delivery of Plasmid DNA Representing Patient Mutation Signatures
Published on: June 23, 2023
Replicase-based plasmid DNA shows anti-tumor activity.
B Leticia Rodriguez1, Zhen Yu, Woon-Gye Chung
1Pharmaceutics Division, College of Pharmacy, University of Texas, Austin, TX 78712, USA.
BMC Cancer
|March 30, 2011
Summary
A novel RNA replicase-based plasmid effectively generates intracellular double-stranded RNA (dsRNA) within tumor cells, significantly inhibiting tumor growth and offering a promising new strategy for cancer therapy.
Area of Science:
- Molecular Biology
- Immunology
- Oncology
Background:
- Double-stranded RNA (dsRNA) exhibits potent anti-tumor properties.
- Intracellular dsRNA is more effective than extracellular dsRNA for inducing apoptosis and immune responses.
- Challenges exist in delivering sufficient synthetic dsRNA to tumors.
Purpose of the Study:
- To investigate the anti-tumor efficacy of an RNA replicase-based plasmid DNA system.
- To determine if in-situ generated dsRNA can inhibit tumor growth.
Main Methods:
- A plasmid encoding sindbis RNA replicase genes (pSIN-β) was designed.
- The anti-tumor activity of pSIN-β was assessed in mouse tumor models (TC-1 lung cancer, B16 melanoma).
- pSIN-β's efficacy was compared against a control plasmid (pCMV-β).
Main Results:
- Transfection with pSIN-β successfully generated dsRNA in tumor cells in vitro.
- pSIN-β significantly delayed tumor growth in vivo compared to pCMV-β.
- Complete tumor eradication was observed in some cases with pSIN-β treatment.
Conclusions:
- RNA replicase-based plasmids can be utilized to generate intracellular dsRNA.
- This approach shows potential for controlling tumor growth.
- Further development may lead to novel cancer therapeutics.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:23Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
02:15Replicative Cell Senescence
Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds the telomeric...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.